Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | TARS1 | P26639 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12448217 | 0.88 | LARS1 (0.73) | LARS1SMN1; SMN2CTSCCASRTARS1 | |
| SCHEMBL30483895 | 0.84 | LARS1 (0.63) | LARS1CASRTARS1SLC1A3SLC1A2 | |
| SCHEMBL14524114 | 0.83 | LARS1 (0.58) | LARS1SMN1; SMN2TARS1KDM4EPPARA | |
| SCHEMBL9753072 | 0.82 | LARS1 (0.62) | LARS1CASRTARS1 | |
| SCHEMBL28173973 | 0.82 | LARS1 (1.00) | LARS1CTSSCTSKTARS1ALDH1A1 | |
| SCHEMBL18019131 | 0.82 | LARS1 (1.00) | LARS1CTSSCTSKTARS1ALDH1A1 | |
| SCHEMBL6248268 | 0.81 | LARS1 (0.68) | LARS1SMN1; SMN2CASRTARS1KDM4E | |
| Hydrochloric Acid SCHEMBL28591958 | 0.81 | LARS1 (0.97) | LARS1CTSSCTSKTARS1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28591957 | 0.81 | LARS1 (0.97) | LARS1CTSSCTSKTARS1ALDH1A1 | |
| SCHEMBL14278272 | 0.79 | CA2 (0.53) | LARS1SMN1; SMN2TARS1KDM4EPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| CN-1914224-B | HCV NS-3 serine protease inhibitors | MEDIVIR AB | 2014-01-29 | — | — | CN | disclosed |
| EP-1692157-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2013-04-17 | — | — | EP | disclosed |
| CN-1914225-B | HCV NS-3 serine protease inhibitors | MEDIVIR AB | 2012-09-26 | — | — | CN | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039623-B2 | Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-18 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208600-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-24 | — | — | US | disclosed |
| CN-1914224-A | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| CN-1914225-A | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| EP-1713822-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073216-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | LARS1 2972/4885SMN1; SMN2 3361/4885CTSB 168/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | LARS1 2972/4885SMN1; SMN2 3361/4885CTSB 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.